03-06-2005: Diversa Corporation and XOMA Ltd. announced the achievement of a milestone under their therapeutic antibody generation and optimization and license agreement for the successful generation of an antibody that binds with sub-picomolar affinity to an undisclosed XOMA target. The milestone achievement will result in an undisclosed payment to Diversa.
"This milestone further demonstrates Diversa's ability to generate high-quality antibody product candidates through its technologies," said Jay M. Short, Ph.D., president and chief executive officer of Diversa Corporation. "We are also pleased to report this therapeutic antibody candidate has shown an affinity that is rare and far exceeds the original design goals."
"This accomplishment highlights the ability of our two companies to work together to rapidly generate a superior antibody that has shown exceptional potency," said John L. Castello, XOMA's chairman, president and chief executive officer. "We believe this therapeutic antibody candidate has the potential to be an important addition to our pipeline and has great potential as a commercially attractive product for the treatment of autoimmune-inflammatory diseases."
Under the terms of the agreement announced in January 2004, Diversa utilizes its proprietary evolution technologies to generate and optimize therapeutic antibodies against targets identified by XOMA, and is entitled to receive undisclosed payments for the achievement of certain milestones as well as royalties on future sales.
This is where you can add this news to your personal favourites
Diversa Corporation and Celunol Corp. announced today that they have completed their previously-announced merger transaction to create a new leader in the global biofuels industry. The combined company, which has been renamed Verenium Corporation, possesses a growing portfolio of specialty ... more
Diversa Corporation announced that it has expanded its collaboration agreement with Cargill to discover and develop novel enzymes for the cost-effective production of a proprietary food-related product designed to help global consumers pursuing healthy lifestyles.
In 2005, Cargill Health a ... more
Diversa Corporation and Bunge Oils, Inc., a part of Bunge North America, have entered into an agreement to discover and develop novel enzymes optimized for the production of edible oil products with enhanced nutritional or health benefits. Edible oil products include bottled vegetable and c ... more
XOMA Ltd. announced receipt of a $750,000 milestone payment under its collaboration with AVEO Pharmaceuticals, Inc. The milestone payment resulted from AVEO's recent initiation of a Phase 2 clinical trial to evaluate its AV-299 antibody for the treatment of non-small cell lung cancer. AV-29 ... more
XOMA Ltd. announced that Steven B. Engle has been named president, chief executive officer and a member of the company's board of directors. Mr. Engle succeeds Jack Castello, the company's former president and chief executive officer, who announced his retirement plans earlier this year. Mr ... more
Jack Castello, Chairman of the Board, President and Chief Executive Officer of XOMA Ltd. , announced his plans to retire. Mr. Castello, 70, chose to announce his retirement plans now to allow adequate time to find the best qualified individual to succeed him and make the management change a ... more